CLINICAL_TRIALS
trial_result
· 2021-08-17
Clinical Trial Update: Study of Octanorm Subcutaneous IG in Patients With PID [Phase 3]
Summary
Phase 3 trial of Octanorm Subcutaneous IG in patients with primary immune deficiency disorder has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Octapharma | Conditions: Primary Immune Deficiency Disorder | Phase 3 | Status: COMPLETED | Results posted: 2021-08-17